Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
Date:2/10/2011

MALVERN, Pa., Feb. 10, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the fourth quarter and the year ended December 31, 2010. The Company also highlighted important commercial, regulatory and clinical development progress during the year 2010 and provided financial and operational guidance for 2011.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

For the quarter ended December 31, 2010, Auxilium reported record net revenues of $61.8 million compared to net revenues of $48.0 million in the fourth quarter of 2009, an increase of 29%.  For the full year 2010, net revenues totaled $211.4 million compared to net revenues of $164.0 million for the full year 2009, an increase of 29%.  

For the quarter ended December 31, 2010, Auxilium reported a net loss of $(16.4) million compared to a net loss of $(11.9) million in the fourth quarter of 2009.  For the full year 2010, Auxilium's net loss was $(51.2) million, compared to a net loss of $(53.5) million for the full year 2009.  

"In 2010, we believe that Auxilium made good progress toward our vision of becoming a rapidly growing, profitable and sustainable biopharmaceutical company.  We achieved record revenues for Testim®, launched XIAFLEX® in the U.S. for Dupuytren's contracture, initiated XIAFLEX global phase III clinical trials for Peyronie's disease and Pfizer, our EU partner, received a positive CHMP opinion for Xiapex® for Dupuytren's contracture," said Armando Anido, Chief Executive Officer and President of Auxilium.  "As we look forward to 2011 and beyond, we expect Testim revenues to continue to grow and believe that the potential global market for XIAFLEX represents a blockbuster opportunity, which could provide sustainable long-term growth and pro
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... , Ph.D., the Company,s Vice President, Biology and ... Relations & Corporate Communications, will present an overview of ... 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) during ...
(Date:5/24/2013)... 2013 Many factors impact tissues targeting ... efflux transporters at the blood-tissue barrier. Even when tissue ... fractions in the tissue rather than the total tissue ... is required to guide lead optimization, predict in vivo ... variables that may impact the likely human clinical dose. ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") ... science-based research and development, sales and marketing of ... announced today that it is awarding exclusive Vestiage ... of Reluma Skin Illuminating Facial Care. Qualified applicants ... sending an email to info(at)vestiageinc(dot)com and putting RELUMA ...
(Date:5/23/2013)... , May 24, 2013 ... angefertigt – Bei der englischen ... , 91 % der Teilnehmer einer groß angelegten ... 20 % laut GINA [*] -Definition [1] als ... Menschen mit Asthma generell einer von vier Denkweisen zugeordnet ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... Inc. (Nasdaq: LXRX ) today announced that Arthur ... will present,at the BIO InvestorForum at The Palace Hotel ... 11:00 a.m. Pacific Time. A live webcast of ... http://www.lexpharma.com . An archived version of the,webcast will ...
... GENZ ) announced today that it has ... the treatment of Hunter syndrome.,Elaprase is an enzyme ... and Genzyme is commercializing the product in Japan ... Shire. Genzyme intends,to launch Elaprase this quarter, following ...
... COHR ) today announced that, as anticipated, on ... letter indicating that,the Company is not currently in compliance ... 4350(e) and 4350(g) due to,its failure to hold an ... 30, 2007. The notice stated that the failure could,serve ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Genzyme Receives Approval to Market Elaprase(R) in Japan 2Genzyme Receives Approval to Market Elaprase(R) in Japan 3Genzyme Receives Approval to Market Elaprase(R) in Japan 4Coherent, Inc. Receives Expected Letter from NASDAQ 2
(Date:5/24/2013)... the world,s largest and fastest growing open-access publishers, today ... in Physics . , A broad scope journal covering ... an open-science and interactive web platform for the research ... , Frontiers, real-time and interactive peer-review enables fast, ... types. With an average of three months from submission ...
(Date:5/24/2013)... the search for medication against Alzheimer,s disease, scientists have focused ... down Amyloid beta (A-beta). After all, it is the accumulation ... of Alzheimer,s patients. Starting point for the formation of A-beta ... the first to unravel the function of APPL the ... fruit flies. , Alessia Soldano (VIB/KU Leuven): "We have ...
(Date:5/23/2013)... 13,000 ships per year, carrying more than 284 million tons ... $1.8 billion dollars in toll fees for the Panama Canal ... million gallons of water are used from Gatun Lake, which ... people living in the isthmus. , However, the advent ... percent of the ships at sea, has demanded change. The ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... -- (Nov. 14, 2011) -- To protect Houston and ... experts recommends building a floodgate across the Houston Ship ... on Galveston Island and the developed west side of ... coastal recreation area to sustainably use wetlands that act ...
... 14, 2011Mary Ann Liebert, Inc., publishers ( http://www.liebertpub.com ... and Technology , a highly innovative, bimonthly peer-reviewed ... has the potential to significantly improve human health, ... and innovative results, essential data, cutting-edge discoveries, thorough ...
... Hull, Bristol and Frankfurt have shown that a new ... on small samples of biological proteins, particularly proteins that ... enhanced form of nuclear magnetic resonance (NMR) spectroscopy, could ... within hours, rather than weeks or months, radically speeding ...
Cached Biology News:Protecting Houston from the next big hurricane 2Protecting Houston from the next big hurricane 3New journal on disruptive science and technology launching in 2012 2New technique enables study of 'challenging' proteins 2
E2F2 protein...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: